Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole, quantity: 20 mg - capsule - excipient ingredients: polysorbate 80; maize starch; mannitol; sodium lauryl sulfate; sucrose; hypromellose; macrogol 6000; purified talc; methacrylic acid copolymer; quinoline yellow; gelatin; titanium dioxide; dibasic sodium phosphate heptahydrate - the relief of heartburn and other symptoms associated with gastro-oesophageal reflux disease (gord). treatment and prevention of relapse in erosive oesophagitis. treatment of duodenal and gastric ulcer. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs (nsaids). prevention of gastric and duodenal ulcers and erosions associated with nsaids in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. long-term prevention of relapse in gastric and duodenal ulceration in patients proven to be h.pylori negative or in whom eradication is inappropriate (eg. the elderly) or ineffective. treatment of zollinger-ellison syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole, quantity: 20 mg - capsule - excipient ingredients: maize starch; quinoline yellow; dibasic sodium phosphate; gelatin; sodium lauryl sulfate; sucrose; titanium dioxide; macrogol 6000; polysorbate 80; hypromellose; purified talc; mannitol; purified water; methacrylic acid copolymer - the relief of heartburn and other symptoms associated with gastro-oesophageal reflux disease (gord). treatment and prevention of relapse in erosive oesophagitis. treatment of duodenal and gastric ulcer. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs (nsaids). prevention of gastric and duodenal ulcers and erosions associated with nsaids in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. long-term prevention of relapse in gastric and duodenal ulceration in patients proven to be h.pylori negative or in whom eradication is inappropriate (eg. the elderly) or ineffective. treatment of zollinger-ellison syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - gadoteric acid, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections - dotarem is indicated, in adults and children, for use in magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - gadoteric acid, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine - dotarem is indicated, in adults and children, for use in magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - gadoteric acid, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections - dotarem is indicated, in adults and children, for use in magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - gadoteric acid, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections - dotarem is indicated, in adults and children, for use in magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; caldiamide sodium hydrate; water for injections; sodium hydroxide - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: caldiamide sodium hydrate; water for injections; sodium hydroxide; hydrochloric acid - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularlity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; caldiamide sodium hydrate - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection - excipient ingredients: caldiamide sodium hydrate; sodium hydroxide; water for injections; hydrochloric acid - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.